Background: Calcineurin inhibitor (CNI)-related nephrotoxicity significantly contributes to chronic renal failure after liver transplantation (LT). Methods: In this prospective study, LT patients with renal dysfunction were randomized to either receive mycophenolate mofetil (MMF) followed by stepwise reduction of CNI with defined minimal CNI-trough levels (MMF group) or to continue their maintenance CNI dose (control group). Immune monitoring was performed in a subgroup of the patients.
Cicinnati V. R.,Yu Z.,Klein C. G.,et al.Combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients is nephro- and hepatoprotective[J].JOURNAL OF HEPATOLOGY.2008,48:S87-S87.doi:10.1016/S0168-8278(08)60211-1.
APA：
Cicinnati, V. R.,Yu, Z.,Klein, C. G.,Sotiropoulos, G.,Sahner, F....&Beckebaum, S..(2008).Combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients is nephro- and hepatoprotective.JOURNAL OF HEPATOLOGY,48,
MLA：
Cicinnati, V. R.,et al."Combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients is nephro- and hepatoprotective".JOURNAL OF HEPATOLOGY 48.(2008):S87-S87
医学